Bronchoalveolar lavage analysis, gallium-67 lung scanning and soluble interleukin-2 receptor levels in asbestos exposure.
This study examined different markers of lung immunologic and inflammatory responses to previous asbestos exposure. We performed bronchoalveolar lavage (BAL) and gallium-67 (67Ga) lung scans and measured serum and BAL soluble interleukin-2 receptor (IL-2R) and angiotensin-converting enzyme (SACE) levels in 32 subjects with a history of significant asbestos exposure, 14 without (EXP) and 18 with (ASB) radiographic evidence of asbestosis. BAL analysis revealed increases in neutrophils in both ASB and EXP when compared to controls (P less than 0.01), which persisted after adjustment for smoking category. Although significant abnormalities of macrophage and total lymphocyte profiles were not found in the study population, lymphocyte subpopulation analysis revealed elevation of BAL T4/T8 ratios in the entire study group (ASB + EXP) when compared to controls (P less than 0.05), independent of smoking category. 67Ga lung scan activity was increased in 56% of ASB and in 36% of EXP: no correlations between positive scans and different radiological and functional parameters could be found. There was no significant elevation of mean SACE, serum, or BAL IL-2R levels in any of the study categories. These data suggest that asbestos exposure may be associated with parenchymal inflammation, even in the absence of clinical criteria for asbestosis. Abnormalities of gallium uptake and of BAL analysis reflect the clinically inapparent inflammation. The increased BAL T4/T8 ratios observed suggest that abnormal local pulmonary immunoregulation may play a role in the pathogenesis of asbestos-related lung diseases.
Delclos
G L
GL
Rockwell-McKelvey Pulmonary Immunology Laboratory, Methodist Hospital, Houston, Texas.
Flitcraft
D G
DG
Brousseau
K P
KP
Windsor
N T
NT
Nelson
D L
DL
Wilson
R K
RK
Lawrence
E C
EC
D000328:Adult; D000911:Antibodies, Monoclonal; D001194:Asbestos / Q000009:adverse effects*; D001195:Asbestosis / Q000175:diagnosis / Q000209:etiology; D001992:Bronchoalveolar Lavage Fluid / Q000032:analysis* / Q000166:cytology; D004797:Enzyme-Linked Immunosorbent Assay; D005710:Gallium Radioisotopes; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D010641:Phenotype; D011877:Radionuclide Imaging; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012907:Smoking / Q000009:adverse effects; D012995:Solubility
D000911:Antibodies, Monoclonal; D005710:Gallium Radioisotopes; D015375:Receptors, Interleukin-2; D001194:Asbestos; D007703:Peptidyl-Dipeptidase A